Danish pharmaceutical company and global leader in diabetes and obesity treatments, including GLP-1 drugs like Ozempic and Wegovy.
Danish pharmaceutical company and global leader in diabetes and obesity treatments, including GLP-1 drugs like Ozempic and Wegovy.
Earns mostly from injectable GLP-1 medicines for diabetes and obesity, sold through pharmacies and health systems, so the business now depends heavily on one drug family. The Novo Nordisk Foundation, through Novo Holdings, controls the votes. It is spending heavily on manufacturing, including three plants taken over from Catalent in 2024.
In one line: Denmark's Eli Lilly..
Moat: wide (IP / patents, scale, brand). Patent-protected GLP-1 franchise plus decades of diabetes-care manufacturing scale and physician trust.
Headquarters: Bagsvaerd, Denmark · Founded: 1923 · Employees: 68,794
Size Novo Nordisk A/S (NOVO-B.CO) is a Denmark Health Care company (Pharmaceuticals: Major) with a market value of $177B, the largest of 60 Denmark companies the cockpit tracks. Shares closed at DKK 271.45 on 18 Nov 2026.
Performance Over six months the shares fell 6.1%, against +17.5% for the median peer and +6.3% for the Denmark market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 5.7% over the last twelve months (peer median +6.1%); the operating margin is 48.3% (peer median 26.6%).
Valuation It trades at 11.8× forward earnings against a peer median of 17.6× (6th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -20 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 31.2 points above its cost of capital (9.9% WACC).
Credit Novo Nordisk A/S has 18 bonds outstanding ($16.9B), rated AA by the agencies and trading like AA at a weighted spread of 70 bp.
Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | DKK 334B | DKK 309B | DKK 290B | DKK 232B | DKK 177B |
| Revenue growth | — | +6% | +25% | +31% | — |
| Gross profit | DKK 274B | DKK 248B | DKK 243B | DKK 193B | DKK 146B |
| EBITDA | DKK 178B | DKK 150B | DKK 148B | DKK 111B | DKK 81.0B |
| Net income | DKK 113B | DKK 102B | DKK 101B | DKK 83.7B | DKK 55.5B |
| Free cash flow | DKK 70.4B | DKK 59.0B | DKK 73.8B | DKK 83.1B | DKK 66.7B |
| Capital expenditure | DKK 82.4B | DKK 90.1B | DKK 51.3B | DKK 38.9B | DKK 14.8B |
| Total debt | DKK 134B | DKK 131B | DKK 103B | DKK 27.0B | DKK 25.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 11.8× | -0.5% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 29.5× | 6.5% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 9.7× | -4.8% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 17.6× | 14.4% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NOVO-B.CO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.9% | +4.1% | 10th lowest of 21 |
| 6-month return | -6.1% | +17.5% | 3rd lowest of 21 |
| Distance from 52-week high | -33.8% | -5.9% | lowest of 21 |
| Revenue growth (TTM) | +5.7% | +6.1% | 10th lowest of 21 |
| Operating margin | 48.3% | 26.6% | 2nd highest of 21 |
| Forward P/E | 11.8× | 17.6× | 6th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -0.5% | 3.7% | 5th least demanding of 20 |
| Growth delivered (Del g) | +19.5% | +6.4% | 2nd highest of 20 |
| Hurdle (Req g minus delivered) | -20.0 pp | -1.3 pp | least demanding of 20 |
| ROIC minus cost of capital | +31.2 pp | +8.1 pp | 2nd highest of 21 |
| EV / EBITDA | 7.3× | 15.2× | 2nd cheapest of 19 |
| Net debt / EBITDA | 0.5× | 1.3× | 5th least indebted of 19 |
| Bond spread | 70 bp | 68 bp | 8th widest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Novo Nordisk A/S NOVO-B.CO | Denmark | $177B | -6% | +6% | 48% | 11.8× | -0.5% | +19.5% |
| Pfizer PFE | United States | $160B | +9% | +1% | 26% | 9.9× | -4.3% | +8.5% |
| Vertex Pharmaceuticals VRTX | United States | $136B | +25% | +11% | 35% | 28.5× | 6.2% | +14.2% |
| Bristol Myers Squibb BMY | United States | $122B | +3% | +4% | 33% | 9.2× | -13.1% | +2.5% |
| Sanofi SAN.PA | France | $114B | +13% | +15% | 27% | 9.7× | -4.8% | +3.9% |
| AstraZeneca AZN.L | United Kingdom | $278B | -2% | +5% | 23% | 17.6× | 14.4% | +15.7% |
| Novartis NOVN.SW | Switzerland | $285B | +11% | -4% | 30% | 17.5× | 1.6% | -0.2% |
| GSK GSK.L | United Kingdom | $97.9B | -3% | +4% | 25% | 10.4× | -0.1% | -0.9% |
| Regeneron Pharmaceuticals REGN | United States | $97.8B | +46% | +19% | 30% | 11.8× | -1.1% | +11.0% |
| Merck & MRK | United States | $340B | +23% | +5% | 18% | 16.4× | 8.3% | +9.3% |
| Roche RO.SW | Switzerland | $381B | +21% | -1% | 31% | 19.9× | 1.7% | +1.1% |
| Chugai Pharmaceutical 4519.T | Japan | $75.2B | -8% | +17% | 50% | 23.7× | 5.0% | +9.8% |
| Merck KGaA MRK.DE | Germany | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% | +3.8% |
| Takeda Pharmaceutical 4502.T | Japan | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% | +7.1% |
| WuXi AppTec 603259.SS | China | $64.2B | +40% | +32% | 43% | 17.0× | 7.2% | +22.3% |
| AbbVie ABBV | United States | $506B | +35% | +11% | 36% | 18.1× | -0.1% | +6.0% |
| Bayer BAYN.DE | Germany | $60.3B | +48% | 0% | 13% | 12.3× | n/a | n/a |
| Galderma GALD.SW | Switzerland | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% | +6.4% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | India | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% | +11.7% |
| Johnson & Johnson JNJ | United States | $656B | +20% | +8% | 26% | 24.2× | 3.7% | +2.7% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | China | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% | +2.7% |
Novo Nordisk A/S has 18 bonds outstanding with $16.9B face value. The agencies rate it AA; its bonds trade like AA. Weighted yield 3.89%, a spread of 70 bp over government bonds.